Scarica l'app Stockscreener
39.61
5.18%
1.95
Precedente Chiudi:
$37.66
Aprire:
$33.375
Volume 24 ore:
1.53M
Relative Volume:
2.60
Capitalizzazione di mercato:
$1.10B
Reddito:
$17.16M
Utile/perdita netta:
$-163.62M
Rapporto P/E:
-6.5148
EPS:
-6.08
Flusso di cassa netto:
$-121.61M
1 W Prestazione:
+17.12%
1M Prestazione:
+16.12%
6M Prestazione:
+90.39%
1 anno Prestazione:
+87.10%
Intervallo 1D:
$33.10
$40.13
Intervallo di 1 settimana:
$33.01
$40.13
Portata 52W:
$12.21
$40.96
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Confronta ANAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
39.61 | 1.04B | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
Share Buyback Program Declared by AnaptysBio (NASDAQ:ANAB) Board of Directors - MarketBeat
AnaptysBio Inc Stock Analysis and ForecastDebt-to-Equity Ratio Analysis & Double Or Triple Capital - earlytimes.in
AnaptysBio (NASDAQ:ANAB) Shares Gap DownTime to Sell? - MarketBeat
AnaptysBio sets $100M stock repurchase plan - MSN
AnaptysBio expands stock repurchase plan by $100 million - Investing.com Nigeria
Tesaro and AnaptysBio Enter Legal Battle Over Suspected Breach in Contract - PharmExec.com
European Equities Close Mixed in Friday Trading; Eurozone Composite PMI Continues to Expand - MarketScreener
GSK, Anaptysbio sue each other over Jemperli revenue - BioPharma Dive
AnaptysBio shares tumble after legal fight with GSK over cancer drug license - Reuters
Legal Battle Puts AnaptysBio's Jemperli Royalties At Risk - Finimize
AnaptysBio files lawsuit against Tesaro and GSK over collaboration agreement By Investing.com - Investing.com South Africa
AnaptysBio (ANAB) Faces Legal Battle with GSK's Subsidiary Over Cancer Drug Agreement - GuruFocus
ANAB Stock Falls After Company Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal - Stocktwits
AnaptysBio Expands Stock Repurchase Plan by $100M - TipRanks
AnaptysBio files lawsuit against Tesaro and GSK over collaboration agreement - Investing.com India
GSK and AnaptysBio Lock Horns Over Jemperli Deal - Citeline News & Insights
AnaptysBio (ANAB) Shares Plunge Amid Legal Battle with GSK - GuruFocus
GSK subsidiary TESARO files lawsuit against AnaptysBio over Jemperli license - Investing.com
[8-K] ANAPTYSBIO, INC Reports Material Event | ANAB SEC FilingForm 8-K - Stock Titan
GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties - Benzinga
AnaptysBio stock falls after filing lawsuit against GSK unit - Investing.com
AnaptysBio drops after litigation with GSK unit (ANAB:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
GSK, AnaptysBio Sue Each Other Over Cancer Drug License - The Wall Street Journal
GSK unit and AnaptysBio trade lawsuits over Jemperli - pharmaphorum
AnaptysBio (ANAB) Expands Stock Buyback Program to $100 Million - GuruFocus
AnaptysBio Launches $100 Million Share Buyback Program - MarketScreener
AnaptysBio Files Complaint Alleging GSK's Tesaro Breached Jemperli Collaboration Deal - MarketScreener
AnaptysBio Sues Tesaro, GSK Over Alleged Breaches of Jemperli License Deal - MarketScreener
Will AnaptysBio Inc. (AN6) stock beat international competition2025 Support & Resistance & Fast Entry Momentum Trade Alerts - newser.com
GSK Faces Legal Challenge Over Alleged Interference with Anaptys - GuruFocus
AnaptysBio Approves Amended $100 Mln Stock Repurchase Plan - Nasdaq
GSK files suit against AnaptysBio over licensing rights - Vox Markets
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary - The Manila Times
AnaptysBio (Nasdaq: ANAB) Announces $100M Stock Buyback Plan Through 2026 - Stock Titan
AnaptysBio files lawsuit against Tesaro over collaboration breach - StreetInsider
GSK’s TESARO Initiates Litigation Against AnaptysBio - AskTraders.com
GSK's Tesaro Sues AnaptysBio Over Jemperli License Breach - MarketScreener
TESARO Pursues Litigation Against AnaptysBio For Alleged Material Breach Of Jemperli Agreement - Nasdaq
GSK arm Tesaro initiates litigation against AnaptysBio - Medical Dialogues
GSK Starts Litigation Against AnaptysBio Inc - MarketWatch
GSK subsidiary TESARO sues AnaptysBio over cancer drug licensing dispute By Investing.com - Investing.com Australia
GSK unit sues AnaptysBio in row over Jemperli rights - Proactive financial news
TESARO Initiates Legal Action Against AnaptysBio Over Jemperli License - TipRanks
GSK subsidiary TESARO sues AnaptysBio over cancer drug licensing dispute - Investing.com
REGGSK PLCInitiation of litigation against AnaptysBio Inc - TradingView
GSK subsidiary Tesaro sues AnaptysBio over Jemperli license breach - MarketScreener
GSK (GSK) Pursues Legal Action Against AnaptysBio Over License D - GuruFocus
TESARO, a GSK subsidiary, initiates litigation against AnaptysBio, Inc. - GSK
AnaptysBio, Inc. authorizes a Buyback Plan. - MarketScreener
Savant Capital LLC Takes Position in AnaptysBio, Inc. $ANAB - MarketBeat
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):